TCM
ONC

Tekla Capital Management’s BeOne Medicines Ltd ONC Stock Holding History

Tekla Capital Management’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$3.74M Hold
20,952
– – 0.15% 91
2023
Q1 		$4.52M Hold
20,952
– – 0.17% 83
2022
Q4 		$4.61M Hold
20,952
– – 0.17% 79
2022
Q3 		$2.83M Sell
20,952
-30,066
-59% -$5.16M 0.12% 101
2022
Q2 		$8.26M Hold
51,018
– – 0.32% 68
2022
Q1 		$9.62M Sell
51,018
-12,754
-20% -$2.71M 0.34% 63
2021
Q4 		$17.3M Hold
63,772
– – 0.56% 47
2021
Q3 		$23.1M Buy
63,772
+17,789
+39% +$5.82M 0.75% 38
2021
Q2 		$15.8M Buy
45,983
+5,594
+14% +$1.85M 0.51% 51
2021
Q1 		$14.1M Buy
40,389
+12,109
+43% +$4.01M 0.48% 55
2020
Q4 		$7.31M Hold
28,280
– – 0.26% 97
2020
Q3 		$8.1M Sell
28,280
-46,704
-62% -$11M 0.3% 75
2020
Q2 		$14.1M Hold
74,984
– – 0.54% 41
2020
Q1 		$9.23M Sell
74,984
-6,105
-8% -$955K 0.42% 47
2019
Q4 		$13.4M Sell
81,089
-13,200
-14% -$2.19M 0.51% 42
2019
Q3 		$11.5M Sell
94,289
-600
-0.6% -$79.7K 0.5% 49
2019
Q2 		$11.8M Hold
94,889
– – 0.48% 51
2019
Q1 		$12.5M Buy
94,889
+9,134
+11% +$1.23M 0.51% 47
2018
Q4 		$12M Hold
85,755
– – 0.51% 43
2018
Q3 		$14.8M Buy
85,755
+30,970
+57% +$5.21M 0.54% 45
2018
Q2 		$8.42M Buy
54,785
+5,289
+11% +$943K 0.32% 72
2018
Q1 		$8.31M Buy
49,496
+23,326
+89% +$3.16M 0.32% 71
2017
Q4 		$2.56M Buy
+26,170
New +$2.4M 0.1% 117
2017
Q2 		– Sell
-87,531
Closed -$3.21M – 150
2017
Q1 		$3.21M Sell
87,531
-29,176
-25% -$1.06M 0.12% 93
2016
Q4 		$3.54M Hold
116,707
– – 0.15% 86
2016
Q3 		$3.6M Hold
116,707
– – 0.14% 97
2016
Q2 		$3.48M Hold
116,707
– – 0.14% 110
2016
Q1 		$3.42M Buy
+116,707
New +$3.31M 0.15% 101

Other funds holding ONC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return

Tekla Capital Management's ONC Position: Q2 2023 in Review

Tekla Capital Management held its BeOne Medicines Ltd (ONC) position steady in Q2 2023 at 20,952 shares worth $3.74M. The position accounts for 0.15% of the portfolio, ranked #91.

Tekla Capital Management first reported a position in ONC in Q1 2016 and has held it in 28 quarters since. The position peaked at $23.1M in Q3 2021. 209 funds tracked by Wall St. Rank hold ONC as of Q2 2023.

  • Tekla Capital Management held 20,952 shares of BeOne Medicines Ltd worth $3.74M as of Q2 2023.
  • Tekla Capital Management left its BeOne Medicines Ltd share count unchanged in Q2 2023.
  • BeOne Medicines Ltd made up 0.15% of Tekla Capital Management's portfolio in Q2 2023, its #91 holding.
  • Tekla Capital Management first reported a position in BeOne Medicines Ltd in Q1 2016 and has held it in 28 quarters since.
  • Tekla Capital Management's BeOne Medicines Ltd position peaked at $23.1M in Q3 2021.
  • 209 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.